NeoDynamics – Latest development
Meet NeoDynamics’ CFO Aaron Wong April 25th. Aaron will give an update on the latest development in the company.
-NeoDynamics recently made a rights issue with net proceeds of 69 mio. SEK – What should the funds be used for?
-US market scalability and volume.
-What should investors expect from the SBI/ACR Breast Imaging Symposium in Savannah, Georgia, taking place on May 16-19?
NeoDynamics AB is a Swedish medical technology company dedicated to improving diagnostics and treatment of cancer. The company has created an innovative precision biopsy system called NeoNavia. This biopsy system builds on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is being evaluated for breast cancer diagnosis in leading clinics in Great Britain, Germany, and Sweden. More than 500 patients have already been tissue sampled by the biopsy system which has now been launched on the market.
NeoDynamics is listed on Spotlight Stock Market in Sweden but will change to Nasdaq First North Growth Market the 2nd of May 2022.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a Corporate Visibility/ Digital IR agreement.